The semaglutide market offers major opportunities in expanding obesity treatments and oral formulations, capitalizing on ...

ALT shares drop over 20% after updated pemvidutide week 48 data; see FDA's stance on non-invasive fibrosis tests. Click here ...

When methadone clinics close over the holidays, the consequences can be devastating for patients, writes Dr. Dustin Kee.

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Many are familiar with CPAP machines to treat sleep apnea, but fewer realize an oral appliance is an effective alternative. So how do you know if you’re a good candidate?

Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injectionsJERUSALEM, Dec. 22, 2025 (GLOBE ...

Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos.

With all the buzzwords surrounding artificial intelligence, from smiling promotions to angry chagrins—promises that it will ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved once-daily Wegovy (R) pill, the first oral GLP-1 medicine for obesity in the US. (3) Wegovy (R) pill is used ...

After 27 years in business, Cytokinetics hopes to pit its own cardiac myosin inhibitor against one it initially developed—now owned by Bristol Myers Squibb—in a market worth billions. Aficamten has a ...

Acute respiratory distress syndrome (ARDS) remains a major challenge in critical care, with mortality rates often exceeding 35–40%. Mechanical ...

Stifel notes that Hold-rated Edgewise Therapeutics (EWTX) reported an EDG-7500 update, with Parts B & C 25mg efficacy/safety data and an interim ...